Clinical Practice Guidelines in Oncology

- Occult Primary

Featured Articles

Harold J. Burstein

Commentary: Incorporation of Crizotinib into the NCCN Guidelines
Gregory J. Riely, Jamie E. Chaft, Marc Ladanyi, and Mark G. Kris

Brief Report: The Changing Paradigm of Treating Pancreatic Neuroendocrine Tumors
Kaunteya Reddy and Renuka Iyer

Crizotinib and Testing for ALK
Alice T. Shaw, Benjamin Solomon, and Mari Mino-Kenudson

Effort Tracking Metrics Provide Data for Optimal Budgeting and Workload Management in Therapeutic Cancer Clinical Trials
Pam James, Patricia Bebee, Linda Beekman, David Browning, Mathew Innes, Jeannie Kain, Theresa Royce-Westcott, and Marcy Waldinger

Management of Neuroendocrine Tumors of Unknown Origin
Ariel Polish, Maxwell T. Vergo, and Mark Agulnik

Carcinoma of Unknown Primary: Focused Evaluation
Gauri R. Varadhachary

Gene Expression Analysis and Immunohistochemistry in Evaluation of Cancer of Unknown Primary: Time for a Patient-Centered Approach
Charles R. Handorf